Advertisement
Advertisement
OrthoPediatrics Corp. (KIDS)
NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Follow
As of 10:40AM EDT. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Performance Outlook
| Previous Close | 32.24 |
| Open | 32.17 |
| Bid | 32.46 x 800 |
| Ask | 32.72 x 900 |
| Day's Range | 32.17 - 32.89 |
| 52 Week Range | 31.81 - 53.50 |
| Volume | |
| Avg. Volume | 83,304 |
| Market Cap | 757.993M |
| Beta (5Y Monthly) | 0.86 |
| PE Ratio (TTM) | 295.09 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Subscribe to Yahoo Finance Plus to view Fair Value for KIDS
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
- OrthoPediatrics Corp.Analyst Report: LivaNova PLCU.K.-based LivaNova was born of a combination between Cyberonics in the U.S. and Sorin in Italy. The medical device firm is primarily focused on cardiovascular and cardiopulmonary solutions (with surgical heart valves, heart-lung machines, and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management and heart valve businesses. LivaNova derives roughly half of its revenue from the U.S. market, another 21% from Europe, and the remainder from the rest of the world.RatingFair ValueEconomic Moat3 days agoMorningstar
- Zacks
Compared to Estimates, OrthoPediatrics (KIDS) Q2 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for OrthoPediatrics (KIDS) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
- Zacks
OrthoPediatrics (KIDS) Reports Q2 Loss, Tops Revenue Estimates
OrthoPediatrics (KIDS) delivered earnings and revenue surprises of 0% and 1.16%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
- Zacks
Pacific Biosciences of California (PACB) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Pacific Biosciences (PACB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
© 2023 Yahoo. All rights reserved.
